Sustainable Pharmaceutical Supply Chains: Green Chemistry Approaches to Drug Production and Distribution

OLUCHUKWU OBINNA OGBUAGU[1], AKACHUKWU OBIANUJU MBATA[2], OBE DESTINY BALOGUN[3], OLAJUMOKE OLADAPO[4], OPEYEMI OLAOLUAWA OJO[5], MURIDZO MUONDE[6]

[1]*Vanderbilt University, USA*

[2]*Kaybat Pharmacy and Stores, Benin, Nigeria*

[3]*Independent Researcher, Lima Ohio, USA*

[4]*Rosenberg Health & Rehabilitation Center, Texas, USA*

[5]*Intern Business Analyst, Tritek Business Consulting, London United Kingdom*

[6]*Africure Pharmaceuticals Namibia*

Abstract- ***The pharmaceutical industry is under increasing pressure to adopt sustainable practices due to its significant environmental footprint, particularly in the areas of drug production and distribution. This paper explores integrating green chemistry principles into pharmaceutical manufacturing and adopting sustainable supply chain strategies to address these challenges. Green chemistry offers innovative solutions by promoting safer chemical processes, energy efficiency, and waste reduction in drug synthesis. Additionally, eco-friendly packaging, waste reduction strategies, and carbon footprint reduction in logistics are essential for creating a more sustainable pharmaceutical supply chain. However, significant challenges remain, including regulatory hurdles, economic constraints, and resistance to change within the industry. Through an analysis of these factors, this paper highlights the importance of policy interventions, technological advancements, and continued research to overcome barriers and promote the widespread adoption of sustainable practices. The findings indicate that, while progress has been made, further innovation, collaboration, and investment are needed to realize a fully sustainable pharmaceutical supply chain. This paper concludes by offering policy recommendations for greener supply chains and suggesting future research directions to enhance the industry's sustainability through technological advancements in manufacturing, packaging, and logistics.***

Indexed Terms- ***Green Chemistry, Sustainable Supply Chain, Pharmaceutical Manufacturing, Eco-friendly Packaging, Carbon Footprint Reduction, Regulatory Challenges***

I. INTRODUCTION

1.1 Overview of Pharmaceutical Supply Chains and Their Environmental Impact

Pharmaceutical supply chains are intricate networks that span across multiple stages, from raw material sourcing and manufacturing to distribution and final delivery to consumers. These global supply chains play a vital role in ensuring the availability of essential medications for public health (Tien, Anh, & Thuc, 2019). However, despite their critical importance, the environmental impact of pharmaceutical supply chains has become a significant concern due to the extensive use of natural resources, generation of waste, and emission of pollutants (David, Wolfender, & Dias, 2015).

The production of pharmaceutical drugs begins with the extraction of raw materials, such as natural plant-based substances or synthetic chemicals. The synthesis of active pharmaceutical ingredients (APIs), which are the core components of drugs, involves energy-intensive processes that often utilize toxic reagents, solvents, and chemicals (Najmi, Javed, Al Bratty, & Alhazmi, 2022). In addition to this, the synthesis of many drugs requires high temperatures and significant energy consumption, further exacerbating the environmental footprint of the manufacturing process.

Moreover, the production of APIs typically generates hazardous waste and byproducts, which pose risks to the environment if not properly managed (Chaachouay & Zidane, 2024).

Beyond manufacturing, the distribution of pharmaceutical products also carries a considerable environmental burden. Pharmaceutical products are often transported over long distances, sometimes across continents, to reach their destinations. This global distribution system relies heavily on air, road, and sea transport, all contributing to greenhouse gas emissions (Ding, 2018). Packaging, another key aspect of pharmaceutical supply chains, is often made from materials that are not biodegradable and contribute to waste accumulation. Plastic, glass, and aluminum are frequently used in drug packaging, resulting in significant environmental waste. While some pharmaceutical companies have made strides in reducing packaging waste, the overall impact of packaging and distribution remains a major concern (Peake, Braund, Tong, & Tremblay, 2015).

The environmental impact of pharmaceutical supply chains is compounded by the fact that they often prioritize cost-effectiveness and speed over environmental considerations. To meet the growing demand for medications, pharmaceutical companies rely on lean, just-in-time production methods that minimize inventory and reduce costs but can lead to waste generation and unsustainable resource use. As a result, while the industry has achieved remarkable advances in terms of innovation and accessibility, it has simultaneously contributed to environmental degradation on a global scale. This calls for a fundamental shift in how pharmaceutical supply chains are designed and managed to ensure that sustainability is integrated into every process step (Alkhouri, 2024).

1.2 The Role of Sustainability in Modern Pharmaceutical Production

Sustainability is becoming an increasingly critical aspect of modern pharmaceutical production as the industry grapples with environmental challenges. The growing awareness of climate change, resource depletion, and pollution has spurred calls for greener, more responsible manufacturing practices within the pharmaceutical sector. Sustainability in pharmaceutical production is an ethical and economic necessity, as it can help reduce costs, improve efficiency, and enhance a company's public image (Rame, Purwanto, & Sudarno, 2024).

In the context of pharmaceutical production, sustainability involves optimizing resource use, reducing waste, and minimizing environmental harm. Traditional pharmaceutical manufacturing practices are energy-intensive and generate large amounts of waste, often including hazardous chemicals that must be carefully disposed of to prevent environmental contamination. On the other hand, sustainability promotes the adoption of cleaner, more efficient technologies and practices that reduce the overall ecological footprint of production. These practices may include using renewable energy sources, water conservation techniques, and adopting zero-waste strategies (Abaku & Odimarha, 2024).

Furthermore, sustainability in pharmaceutical production is increasingly linked to regulatory and market pressures. In recent years, there has been a growing recognition among regulatory bodies and investors that environmental stewardship is essential for long-term business success. The introduction of stricter environmental regulations, such as limits on greenhouse gas emissions and mandatory waste management procedures, has forced pharmaceutical companies to reconsider their manufacturing methods. At the same time, there is increasing consumer demand for environmentally friendly products. Patients, healthcare providers, and investors alike are calling for more sustainable practices from pharmaceutical companies, and those that fail to meet these expectations risk damaging their reputations and losing market share (David et al., 2015).

Sustainable pharmaceutical production also has significant public health benefits. For example, reducing the environmental impact of drug production can help prevent pollution-related health problems. Pharmaceuticals are often detected in wastewater and the environment, where they can harm wildlife and ecosystems (Fuller et al., 2022). By adopting more sustainable production methods, pharmaceutical companies can reduce the release of these substances into the environment, contributing to cleaner air and water. Furthermore, sustainability initiatives can lead

to more affordable and accessible medicines, as resource optimization and waste reduction can lower production costs and reduce price volatility in the supply chain (Sherman et al., 2020).

1.3 Introduction to Green Chemistry as a Key Solution
Green chemistry, a relatively recent discipline that focuses on designing chemical products and processes that are environmentally benign, is emerging as a key solution to the environmental challenges posed by pharmaceutical manufacturing. Green chemistry emphasizes the reduction or elimination of the use and generation of hazardous substances in the design, synthesis, and formulation of chemicals, making it highly relevant to the pharmaceutical industry. By applying green chemistry principles to drug production, companies can reduce toxic waste, decrease energy consumption, and minimize the use of harmful chemicals, resulting in cleaner and more sustainable manufacturing processes (Andraos & Matlack, 2022).

One of the core principles of green chemistry is the use of renewable feedstocks, which are sourced from natural, biodegradable materials, rather than non-renewable, fossil-based resources. In pharmaceutical manufacturing, this could mean using plant-based or biotechnological processes to produce active ingredients instead of relying on synthetic chemicals derived from petroleum. Green chemistry also emphasizes the design of more efficient reactions that require less energy and generate fewer byproducts. For example, by employing catalytic processes, the use of toxic solvents and reagents can be minimized, reducing the environmental impact of the production process (Llevot & Meier, 2016).

The potential of green chemistry in pharmaceutical production is vast, but it is particularly valuable in addressing two key challenges: reducing waste and improving the sustainability of drug synthesis. In traditional pharmaceutical manufacturing, the use of hazardous chemicals and solvents often leads to the generation of toxic waste, which must be carefully managed and disposed of. Green chemistry aims to eliminate or reduce the need for such chemicals, resulting in cleaner production processes that are less damaging to the environment. Furthermore, applying green chemistry can lead to more efficient drug synthesis methods, reducing the energy required for production and enabling the use of alternative, less harmful substances (Kar, Sanderson, Roy, Benfenati, & Leszczynski, 2021).

By adopting green chemistry principles, the pharmaceutical industry can improve its environmental performance and Green chemistry technologies are often more cost-effective in the long run, as they reduce the need for expensive reagents, minimize waste disposal costs, and streamline production processes. Moreover, green chemistry can help pharmaceutical companies stay ahead of regulatory requirements, as governments around the world are increasingly mandating stricter environmental standards.

1.4 Research Objectives and Significance
The primary objective of this research is to explore how green chemistry can be integrated into pharmaceutical supply chains to mitigate the environmental impact of drug production and distribution. The paper will examine the role of green chemistry in reducing waste generation, minimizing energy consumption, and improving the sustainability of pharmaceutical manufacturing processes. It will also investigate how green chemistry can help pharmaceutical companies address key environmental challenges, such as reducing carbon emissions and promoting the use of renewable resources.

This research will comprehensively analyze green chemistry applications in the pharmaceutical industry, offering insights into the practical benefits and limitations of adopting these techniques. By reviewing existing case studies and current industry practices, the paper aims to identify the most effective green chemistry strategies for reducing the environmental footprint of pharmaceutical supply chains. Additionally, it will examine the challenges associated with implementing green chemistry in the pharmaceutical industry, including regulatory hurdles, financial constraints, and technological limitations.

The significance of this research lies in its potential to provide actionable recommendations for pharmaceutical companies seeking to adopt more sustainable practices. With the growing pressure from stakeholders, including consumers, investors, and

regulatory bodies, the pharmaceutical industry must explore ways to integrate sustainability into its operations. This research aims to help bridge the gap between environmental goals and business objectives, offering solutions that can enhance pharmaceutical supply chains' ecological and economic sustainability. By shedding light on the potential of green chemistry in transforming the pharmaceutical industry, this research contributes to the ongoing conversation on sustainability in healthcare. The findings of this study can help shape future policy decisions, guide industry practices, and drive further research into greener pharmaceutical manufacturing and distribution models. Ultimately, this research aims to foster a more sustainable pharmaceutical industry that not only improves public health but also preserves the health of the planet for future generations.

II. GREEN CHEMISTRY PRINCIPLES IN PHARMACEUTICAL MANUFACTURING

2.1 Definition and Core Principles of Green Chemistry

Green chemistry, also known as sustainable chemistry, is an evolving field that seeks to design and apply chemical processes that minimize the use and generation of hazardous substances. In essence, green chemistry strives to make chemical products and processes safer for both humans and the environment. It integrates sustainability principles into the molecular design and chemical synthesis processes, with an emphasis on reducing environmental impacts throughout the lifecycle of chemical products. The aim is to prevent pollution at its source, rather than managing it as a waste product after it has been created (Sheldon, 2018).

The core principles of green chemistry were introduced in the 1990s by chemist Paul Anastas and his colleagues. These principles provide a framework for developing more environmentally friendly and economically viable chemical processes, emphasizing efficiency, safety, and resource conservation. While the specific applications of green chemistry may vary across industries, the following twelve principles form the foundation of this approach (Krasnodębski, 2022):

- Prevention of Waste: This principle encourages the design of processes that minimize or eliminate waste generation. By focusing on the efficient use of materials and energy, waste can be reduced at the source, which in turn reduces disposal costs and environmental harm.
- Atom Economy: Atom economy emphasizes the design of reactions that maximize the incorporation of all atoms in the starting materials into the final product. This reduces the need for excess reagents and solvents, which are often discarded as waste.
- Less Hazardous Chemical Synthesis: This principle advocates for the selection of reagents, solvents, and reaction conditions that are less toxic and hazardous. It promotes the use of safer chemicals and avoids substances that pose risks to human health and the environment.
- Design for Energy Efficiency: Green chemistry encourages the use of energy-efficient processes that minimize the need for high temperatures or pressures. This can be achieved through more efficient catalysts and lower energy consumption reaction conditions.
- Use of Renewable Feedstocks: Renewable, biodegradable materials as raw materials are central to green chemistry. This reduces dependence on non-renewable resources, such as petroleum, and ensures the sustainability of the chemical process.
- Reduce Derivatives: The use of unnecessary derivatization reactions, such as protecting groups, should be avoided. These reactions often require additional reagents and generate waste.
- Catalysis: Green chemistry promotes the use of catalysts to drive chemical reactions more efficiently, often under milder conditions, which reduces the need for stoichiometric reagents and energy-intensive steps.
- Design for Degradation: Chemical products should be designed to break down into non-toxic substances after their useful life. This helps to prevent long-term environmental contamination from chemicals that persist in the environment.
- Real-time Analysis for Pollution Prevention: Real-time monitoring and analytical techniques are important for controlling processes, ensuring that pollutants are prevented at the source and emissions are minimized.
- Safer Chemistry for Accident Prevention: The principle advocates for designing chemical processes and products that are inherently safer by

preventing accidents or dangerous conditions, reducing the risk of spills, fires, or toxic releases.

These principles offer a transformative drug development and production approach when applied to pharmaceutical manufacturing. By emphasizing waste reduction, energy efficiency, and the use of non-toxic and renewable materials, green chemistry principles align with the growing need for more sustainable practices in the pharmaceutical industry. They also pave the way for innovation in drug synthesis, offering a potential for cleaner and more cost-effective production methods (Olaleye, Mokogwu, Olufemi-Phillips, & Adewale, 2024).

2.2 Application of Green Chemistry in Drug Synthesis
The application of green chemistry in drug synthesis is a crucial step toward reducing the environmental impact of pharmaceutical production. In traditional drug synthesis, toxic reagents, hazardous solvents, and high-energy-consuming processes are commonplace. Green chemistry aims to replace these harmful practices with safer, more sustainable alternatives, ultimately transforming the way pharmaceutical drugs are manufactured. One of the most significant applications of green chemistry in drug synthesis is the use of *green solvents* in place of traditional solvents, which are often toxic and non-biodegradable. Green solvents like water, supercritical CO_2, or ionic liquids are less hazardous and have lower environmental impacts. These solvents can provide similar or even better efficiencies compared to traditional ones while reducing toxicity and environmental contamination (Kar et al., 2021).

Another application is the implementation of *atom-efficient reactions*, which maximize the incorporation of reactants into the final product, minimizing the need for wasteful byproducts. In traditional pharmaceutical synthesis, chemical reactions often produce large quantities of waste, such as unreacted reagents and solvents. By using reactions with high atom economy, the amount of waste generated can be significantly reduced, and the overall efficiency of the process can be improved (Ogundairo et al., 2024; Olaleye et al., 2024).

Additionally, *catalysis* plays a crucial role in green chemistry-based drug synthesis. Catalysts allow chemical reactions to proceed more efficiently, often at milder temperatures and pressures. This reduces the need for excessive energy and toxic reagents. Catalytic processes can also improve the selectivity of reactions, allowing for more precise control over the product formation. For example, asymmetric catalysis, which helps create enantiomerically pure compounds, is particularly useful in the pharmaceutical industry, where the purity of drug compounds is crucial.

Renewable feedstocks are another significant application of green chemistry in drug synthesis. Many pharmaceutical compounds are traditionally derived from non-renewable petroleum-based raw materials that contribute to environmental pollution. Green chemistry encourages the use of bio-based feedstocks, such as plant-derived materials or renewable bioprocesses, which can help reduce dependence on fossil fuels and improve the sustainability of pharmaceutical manufacturing (Ogbeta, Mbata, & Katas, 2024; Ogbonna, Oparaocha, Anyanwu, & Innocent, 2024).

Furthermore, *continuous flow processes* are becoming increasingly popular in green chemistry-based drug synthesis. Unlike traditional batch processes, continuous flow systems involve the uninterrupted movement of reactants through a reactor, providing better control over reaction conditions. These systems can reduce waste, increase efficiency, and safer operation, as they often eliminate the need for large quantities of hazardous chemicals.

In addition to these methods, green synthetic routes have gained traction in drug manufacturing. Green synthetic routes involve redesigning reaction pathways to reduce the number of steps, eliminate harmful reagents, and optimize reaction conditions to be more energy-efficient. For instance, one-step reactions combining multiple functions in a single step can significantly reduce the need for multiple solvents and reagents, reducing waste and cost (M. C. Kelvin-Agwu, M. O. Adelodun, G. T. Igwama, & E. C. Anyanwu, 2024b; Majebi, Adelodun, & Anyanwu, 2024).

2.3 Case Studies of Green Chemistry Implementation in the Pharmaceutical Industry

The implementation of green chemistry principles in the pharmaceutical industry has led to several innovative approaches that reduce environmental impact and enhance the sustainability of drug production. Several pharmaceutical companies have successfully adopted green chemistry practices, showcasing how these principles can be integrated into real-world manufacturing processes.

One prominent example is the application of green chemistry in the synthesis of *ibuprofen*, a widely used anti-inflammatory drug. Traditional methods for synthesizing ibuprofen involved hazardous reagents, solvents, and several synthetic steps. However, a more sustainable process for ibuprofen production was developed by applying green chemistry principles, including atom-efficient reactions, renewable feedstocks, and safer solvents. This process, which was introduced by the pharmaceutical company *BASF*, reduced the number of synthetic steps and waste generated while improving overall yields. The new process also eliminated the use of hazardous reagents, making it safer and more environmentally friendly (Kar et al., 2021).

Another notable case is the development of a greener process for producing *celecoxib*, a drug used to treat pain and inflammation. The traditional synthetic route for celecoxib used several hazardous reagents and solvents, resulting in much waste. By applying green chemistry techniques, including the use of non-toxic solvents and efficient catalytic reactions, the new process for celecoxib production reduced waste generation and improved the sustainability of the drug's synthesis (Quiñones & Pierre, 2019).

In addition, *Novartis*, a global pharmaceutical company, has embraced green chemistry in its manufacturing processes to reduce its environmental footprint. The company has focused on replacing toxic solvents with more environmentally friendly alternatives, such as water or supercritical CO_2. It has also implemented energy-saving technologies and optimized reaction conditions to reduce the overall energy consumption of its drug synthesis processes. As a result, Novartis has significantly reduced its carbon footprint and improved its manufacturing operations' sustainability (Veleva, Cue Jr, & Todorova, 2018).

Another example comes from *GlaxoSmithKline* (GSK), which has integrated green chemistry principles into the production of its antimalarial drug *dihydroartemisinin*. By utilizing renewable feedstocks, optimizing reaction conditions, and reducing waste, GSK has developed a more sustainable synthesis route for the drug. The new process reduced environmental impact and lowered production costs, showcasing the economic benefits of green chemistry in the pharmaceutical industry (G Ferreira, D Nicoletti, de C da Silva, & F Ferreira, 2016).

These case studies demonstrate the tangible benefits of applying green chemistry in pharmaceutical manufacturing. Pharmaceutical companies can significantly reduce waste, energy consumption, and hazardous chemical usage by incorporating green chemistry principles into their processes. Moreover, these practices often lead to cost savings, improved efficiency, and enhanced product quality. As more pharmaceutical companies adopt green chemistry techniques, the industry is expected to continue to evolve toward more sustainable and environmentally friendly practices.

III. SUSTAINABLE SUPPLY CHAIN STRATEGIES IN DRUG DISTRIBUTION

3.1 Eco-friendly Packaging and Waste Reduction Strategies

Eco-friendly packaging is a vital aspect of sustainable supply chains, particularly in the pharmaceutical industry, where product protection and compliance with regulatory standards must be balanced with environmental considerations. Traditional pharmaceutical packaging materials, such as plastic, aluminum, and non-biodegradable substances, contribute significantly to waste generation and environmental pollution. In response, eco-friendly packaging strategies aim to minimize waste, use renewable or recyclable materials, and reduce the overall environmental impact of packaging throughout its lifecycle (Eyo-Udo, Abbey, & Olaleye, 2024).

The adoption of biodegradable, compostable, or recyclable packaging materials is one of the primary ways pharmaceutical companies are transitioning to greener packaging options. For instance, companies

are increasingly moving away from plastic packaging in favor of alternatives such as paper-based packaging, which can be sourced from sustainably managed forests. When certified by recognized environmental organizations like the Forest Stewardship Council (FSC), paper ensures that the materials are harvested in an environmentally responsible manner. Many pharmaceutical companies also turn to bioplastics derived from renewable resources such as corn or sugarcane. These bioplastics break down more easily in the environment and offer a promising alternative to petroleum-based plastics (M. C. Kelvin-Agwu, M. O. Adelodun, G. T. Igwama, & E. C. Anyanwu, 2024a, 2024c).

Another key strategy involves reducing the size and weight of packaging. By optimizing the packaging design, companies can use fewer materials and reduce waste generation without compromising product safety. Packaging optimization also leads to logistical efficiencies, as smaller and lighter packages reduce the volume and weight of transported goods, thus lowering transportation costs and the carbon footprint of the distribution process. For example, reducing the size of pill blister packs can minimize packaging waste and the space required for storage and transportation.
Many pharmaceutical companies are adopting returnable and reusable packaging systems to further reduce waste. These systems involve containers, such as bulk drums or pallets, which are reused multiple times before being recycled or retired. Such approaches are commonly seen in the bulk transportation of active pharmaceutical ingredients (APIs) or over-the-counter products, where large quantities are shipped in returnable containers. These strategies help reduce both the amount of packaging used and the frequency of repurchasing new packaging materials (Drakeford & Majebi, 2024b; Edoh, Chigboh, Zouo, & Olamijuwon, 2024).

Moreover, *supply chain transparency* is essential to waste reduction efforts. By implementing tracking systems and adopting green certifications, companies can gain insight into the environmental impact of their packaging choices, ensuring compliance with environmental standards and monitoring progress over time. Life Cycle Assessment (LCA) methodologies enable companies to evaluate the environmental impact of packaging materials from raw material extraction to disposal or recycling, helping businesses make more informed decisions when selecting packaging materials (Venkatesh, Kang, Wang, Zhong, & Zhang, 2020).

The integration of *circular economy* principles in pharmaceutical packaging is another emerging trend. The circular economy model emphasizes the recycling and reuse of materials, creating a closed-loop system where end-of-life products are repurposed or returned to the production cycle. This concept is increasingly applied to packaging, where companies aim to design products with minimal waste generation and maximum recyclability. With advancements in sorting and recycling technologies, more pharmaceutical packaging can be reclaimed and repurposed, reducing the need for virgin materials (Drakeford & Majebi, 2024a, 2024c).

3.2 Carbon Footprint Reduction in Pharmaceutical Logistics

Pharmaceutical logistics is a critical supply chain element involving drug storage, handling, and transportation. Like many other industries, the pharmaceutical sector has faced growing pressure to reduce its carbon footprint and mitigate its environmental impact, particularly in the transportation and storage phases of logistics, which are among the most energy-intensive operations.

One of the primary ways pharmaceutical companies reduce their logistics carbon footprint is by optimizing transportation routes. The efficient use of transportation resources can significantly lower greenhouse gas emissions, reduce fuel consumption, and minimize congestion. By implementing route optimization software and geographic information systems (GIS), companies can identify the most efficient paths for delivery trucks, ensuring minimal travel time and distance. This reduces fuel usage and ensures on-time deliveries, which is particularly important in the pharmaceutical industry, where the timely delivery of temperature-sensitive products is crucial (Low, Halim, Adhitya, Chew, & Sharratt, 2016).

Another significant strategy involves the adoption of *green transportation modes*. With increasing attention to sustainability, the pharmaceutical industry is

exploring alternatives to traditional, fuel-powered vehicles. Electric trucks and hybrid vehicles are being integrated into pharmaceutical logistics fleets as part of a broader push toward decarbonizing transportation. Electric vehicles (EVs) produce zero emissions during operation and are becoming more viable as the infrastructure for EV charging stations expands. Additionally, many pharmaceutical companies are turning to *rail transportation*, which is more energy-efficient than road transport, especially for long-distance shipments of non-perishable products (Ayo-Farai et al., 2024; Banji, Adekola, & Dada, 2024).

Incorporating *sustainable packaging* into the logistics process also plays a key role in carbon footprint reduction. By reducing the volume and weight of packaging, pharmaceutical companies can reduce the overall carbon emissions from transportation. Lighter and more compact packaging requires less fuel to transport, and the use of recyclable or reusable packaging further minimizes the environmental impact of the logistics operation. Moreover, using packaging optimized for stacking can increase storage efficiency, reduce transportation costs, and lower emissions associated with transporting goods (Ding, 2018).

Energy-efficient *warehousing* practices are another important aspect of reducing the carbon footprint of pharmaceutical logistics. Pharmaceutical warehouses are often temperature-sensitive environments that require controlled climates to ensure product quality. Implementing energy-saving systems such as LED lighting, motion sensors, and advanced temperature control systems can significantly reduce energy consumption. Some pharmaceutical companies have embraced *solar energy* solutions to power their warehouses, further contributing to reducing their carbon footprint.

Moreover, *sustainability certifications* are becoming increasingly important in pharmaceutical logistics. Various organizations, such as the Carbon Trust, offer carbon reduction certifications for companies that demonstrate efforts to minimize their carbon emissions. Pharmaceutical companies that achieve these certifications improve their environmental performance, enhance their reputation, and meet the growing demand for sustainability from consumers, investors, and regulators (Alemede, Nwankwo, Igwama, Olaboye, & Anyanwu, 2024a; Arowoogun et al., 2024).

3.3 Digitalization and AI-driven Optimizations for Sustainable Distribution

The digitalization of the pharmaceutical supply chain has brought about transformative changes in distribution processes, offering opportunities to optimize efficiency, reduce waste, and lower environmental impact. Through the integration of digital tools, pharmaceutical companies can now manage their supply chains more effectively and with greater precision.

One of the most impactful digital technologies in the pharmaceutical industry is *artificial intelligence (AI)*, which enables data-driven decision-making and predictive analytics. AI algorithms can analyze vast amounts of data to optimize inventory management, forecast demand, and improve warehouse management. By ensuring that the right products are in the right place at the right time, AI can reduce excess stock and waste, preventing the overproduction and underutilization of resources. This also helps minimize transportation emissions by ensuring distribution efforts align with actual demand rather than relying on over-ordering (Adelodun & Anyanwu, 2024b; Alemede, Nwankwo, Igwama, Olaboye, & Anyanwu, 2024b).

In addition to AI, Internet of Things (IoT) devices are critical in optimizing distribution. IoT-enabled sensors are used to monitor and track pharmaceutical products during their transit and storage. For instance, temperature-sensitive medications require constant temperature monitoring during shipment, and IoT devices can provide real-time data on environmental conditions, ensuring compliance with regulatory standards and reducing the risk of product spoilage. This digital monitoring enhances operational efficiency by preventing unnecessary returns or product losses due to improper handling, reducing both environmental impact and costs.

The integration of *blockchain technology* in pharmaceutical supply chains is another avenue for improving sustainability in distribution. Blockchain offers transparency, traceability, and security across

the entire supply chain. It allows stakeholders to track the journey of pharmaceutical products from manufacturing to distribution, ensuring that all transactions and movements are recorded in a tamper-proof ledger. This transparency can reduce fraud, improve product safety, and enhance the overall efficiency of the supply chain, reducing waste and minimizing carbon emissions (Adelodun & Anyanwu, 2024a, 2024c).

Cloud-based platforms also contribute to sustainability in pharmaceutical distribution by enabling seamless communication and collaboration among supply chain partners. These platforms allow for the real-time sharing of information, which enhances the coordination of manufacturing, distribution, and retail operations. By synchronizing the supply chain and reducing delays, these platforms help to ensure that resources are used more efficiently, minimizing energy consumption and lowering carbon footprints. In addition, *smart logistics solutions* leverage digital tools to optimize vehicle routes, monitor traffic conditions, and calculate the most energy-efficient transportation methods. By implementing real-time monitoring systems, companies can also reduce empty miles, where vehicles travel without carrying any goods. This further reduces fuel consumption and environmental impact (Abbey, Olaleye, Mokogwu, Olufemi-Phillips, & Adewale, 2024).

The convergence of digital technologies in pharmaceutical distribution ultimately leads to more sustainable practices by enhancing transparency, reducing waste, improving resource management, and optimizing transportation. As the industry continues to embrace digitalization and AI, sustainable practices in drug distribution will become more widespread and effective, contributing to the ongoing transformation of the pharmaceutical supply chain into a greener, more sustainable system (Kumar et al., 2022).

IV. CHALLENGES AND BARRIERS TO IMPLEMENTATION

4.1 Regulatory and Compliance Challenges

The pharmaceutical industry is one of the most heavily regulated sectors globally, with stringent rules governing everything from product safety to manufacturing processes. While essential for ensuring patient safety, this regulatory environment presents significant challenges for implementing sustainable practices, including green chemistry and eco-friendly supply chain strategies. The process of complying with multiple, sometimes conflicting, regulations across different regions can be complex and resource-intensive.

One of the key challenges is the lack of universally accepted standards for sustainability in pharmaceutical manufacturing and distribution. Regulatory frameworks such as the *Good Manufacturing Practices (GMP)* and *Good Distribution Practices (GDP)* ensure that pharmaceutical products are consistently produced and controlled according to quality standards. However, these regulations often do not explicitly address sustainability or environmental considerations. This leaves companies without clear guidelines on how to integrate green chemistry principles, eco-friendly packaging, or carbon reduction measures within the existing regulatory framework (Ding, 2018).

Regulatory bodies often do not recognize or accept green alternatives to traditional processes or materials due to concerns over product quality or efficacy. For example, switching to bio-based solvents in synthesizing active pharmaceutical ingredients (APIs) may face regulatory hurdles, as these solvents might not be as widely validated or recognized as their petrochemical counterparts. Regulatory bodies, such as the *U.S. Food and Drug Administration (FDA)* or the *European Medicines Agency (EMA)*, require extensive data and testing to approve new materials and methods, which can delay the adoption of more sustainable practices (M. Kelvin-Agwu, M. O. Adelodun, G. T. Igwama, & E. C. Anyanwu, 2024; M. C. Kelvin-Agwu et al., 2024a).

Additionally, sustainability certifications, critical for ensuring eco-friendly practices, are not always aligned with pharmaceutical regulations. For example, achieving certifications such as the *Forest Stewardship Council (FSC)* for sustainable paper packaging or ISO certifications for sustainability may not automatically meet the compliance standards required for pharmaceutical packaging, which must also meet strict quality, safety, and regulatory

guidelines. Therefore, navigating the approval process for new materials and sustainability practices can be a lengthy and resource-heavy endeavor, particularly for small- and medium-sized enterprises (SMEs) that may lack larger pharmaceutical corporations' regulatory expertise and infrastructure.

Another challenge arises from the growing number of global regulations concerning sustainability. Pharmaceutical companies operating internationally must adhere to the regulatory standards of each country in which they operate. For instance, the U.S. has its own set of regulations, while the European Union enforces its *REACH* regulation for chemical substances and the *Circular Economy Action Plan*. This multiplicity of regulations creates a complicated landscape for global supply chains, as companies must ensure that their sustainability measures comply with the rules in every jurisdiction they operate in, which can require significant investment in compliance efforts (Drakeford & Majebi, 2024a, 2024d).

Lastly, the implementation of environmental regulations can be costly. The certification processes, documentation requirements, and testing needed to demonstrate compliance with green standards can place a financial burden on companies, especially in the case of new green technologies or materials. While these costs may be justified in the long term due to the potential for cost savings and positive brand differentiation, they can still pose significant challenges in the short term.

4.2 Economic and Technological Constraints

Economic and technological constraints are among the most significant barriers to adopting sustainable practices in the pharmaceutical industry. Developing and implementing green chemistry principles, eco-friendly packaging solutions, and carbon footprint reduction strategies often require substantial financial investment, which may not be immediately feasible for all companies, especially those with limited resources.

From an economic standpoint, the initial costs of transitioning to more sustainable practices can be prohibitively high. For example, developing more environmentally friendly production processes may require significant capital expenditures in research and development, equipment upgrades, or facility modifications. Companies may need to invest in new technologies, such as advanced filtration systems for waste treatment, energy-efficient machinery, or automated systems for tracking and reducing resource consumption. These investments can be difficult to justify when the financial returns are uncertain or distant, especially for companies that are already facing tight margins and competitive pressures in the market.

Moreover, the adoption of green alternatives may increase operational costs in the short term. While long-term savings can be achieved through efficiencies and waste reduction, the higher upfront costs of sustainable materials, technologies, and processes may deter companies from transitioning. For instance, sustainable packaging materials, such as biodegradable plastics or recyclable paper, may be more expensive than conventional plastic packaging. Similarly, developing new sustainable drug synthesis methods may incur additional costs due to the need for specialized equipment and reagents (Nižetić, Djilali, Papadopoulos, & Rodrigues, 2019).

Technologically, the pharmaceutical industry faces challenges in adopting cutting-edge green technologies due to the complexities of drug development and manufacturing processes. Many green technologies, such as those involving new bio-based solvents, catalysts, or renewable energy sources, are still in the experimental or pilot stages and may not yet be fully scalable for large-scale pharmaceutical manufacturing. Integrating renewable energy sources, such as solar or wind power, into pharmaceutical manufacturing facilities requires substantial infrastructure changes and long-term planning, which can be challenging for companies with existing operations. The availability of suitable green technologies that meet the stringent standards of the pharmaceutical industry remains limited, creating a gap between sustainability goals and technological solutions.

The industry’s reliance on legacy systems and equipment also presents a technological barrier. Many pharmaceutical manufacturing facilities are built on older technologies not designed for sustainability. Retrofitting these facilities to accommodate more

energy-efficient systems or implement new green chemistry techniques can be costly and time-consuming. Some companies may opt to continue using existing infrastructure, as upgrading to more sustainable technologies may be perceived as too expensive or disruptive to operations (Arden et al., 2021).

4.3 Resistance to Change within the Industry

Resistance to change is a major barrier to implementing sustainable practices in the pharmaceutical industry. This resistance is often rooted in several factors, including established corporate cultures, perceived risks, and the reluctance to deviate from traditional methods that have long been successful in ensuring product quality and regulatory compliance.

Pharmaceutical companies, especially larger ones, tend to have established processes and a deeply ingrained corporate culture focused on efficiency, risk mitigation, and profit maximization. Adopting new, untested technologies and processes can be seen as a potential risk to production efficiency and product quality. Many companies are understandably hesitant to adopt green chemistry methods, eco-friendly packaging solutions, or alternative distribution models without clear, immediate evidence that these strategies will meet regulatory standards and customer expectations (Baranes, 2016).

The conservative nature of the pharmaceutical industry, driven by a focus on patient safety and regulatory compliance, contributes to this resistance to change. The rigorous validation processes required for new technologies and materials make it difficult for companies to adopt innovations quickly. Additionally, the long timelines for drug development and manufacturing can create a reluctance to adopt unproven technologies, as the potential for failure is perceived as high (Wingate, 2016).

Another aspect of resistance stems from the complexity and uncertainty surrounding the implementation of sustainable practices. For example, pharmaceutical companies may face challenges aligning sustainability efforts with existing supply chain structures. This may require rethinking supplier relationships, renegotiating contracts, and investing in new employee training programs. These changes can be seen as disruptive, especially in organizations that have grown accustomed to their current operating models. Furthermore, the lack of immediate financial returns from sustainability initiatives can make gaining buy-in from stakeholders who prioritize short-term profitability difficult (Singh, Kumar, & Kumar, 2016).

Finally, the lack of clear incentives for sustainability within the pharmaceutical industry contributes to the resistance to change. While consumer demand for sustainable products is increasing, it has not yet reached a level that compels all pharmaceutical companies to make significant changes. The cost savings and potential for regulatory incentives associated with green practices may not be immediately apparent, further dampening the willingness to invest in sustainability.

V. CONCLUSION AND FUTURE DIRECTIONS

5.1 Summary of Key Findings

The pharmaceutical industry increasingly acknowledges the need for sustainable practices to address the environmental and ethical challenges associated with traditional production and distribution methods. Key findings from this discussion highlight the critical role that green chemistry plays in transforming pharmaceutical manufacturing processes. Green chemistry principles, such as the use of safer solvents and energy-efficient reaction methods, not only reduce the environmental impact but also enhance product quality and cost-efficiency in the long term. Moreover, sustainable supply chain strategies, including eco-friendly packaging and carbon footprint reduction, have shown promise in mitigating the environmental effects of pharmaceutical logistics.

However, significant barriers remain, including regulatory hurdles, economic constraints, and technological limitations. The complexity of aligning sustainability with stringent industry regulations and the high costs of adopting new technologies has slowed the industry's progress toward greener practices. Additionally, resistance to change within the industry, driven by traditional operational models and

a risk-averse corporate culture, poses a substantial challenge to widespread implementation.

Despite these obstacles, the pharmaceutical sector has made strides in integrating sustainability into its operations, with increasing attention paid to green chemistry, waste reduction, and eco-conscious logistics.

5.2 Policy Recommendations for Greener Pharmaceutical Supply Chains

To foster a more sustainable pharmaceutical industry, several policy recommendations are essential. First, regulatory frameworks should evolve to integrate clear guidelines and incentives for sustainable practices. Regulatory bodies, such as the *FDA* and *EMA*, could provide frameworks that encourage green chemistry by outlining clear pathways for the approval of eco-friendly materials and production methods. Governments could also introduce tax incentives or subsidies for companies that meet sustainability goals, effectively offsetting the initial costs of transitioning to greener practices.

International collaborations between regulatory authorities and pharmaceutical companies are crucial in harmonizing sustainability standards across global supply chains. This would reduce the complexity of compliance for multinational companies and foster broader adoption of sustainable practices. Furthermore, policies aimed at reducing waste in pharmaceutical packaging and promoting recyclable or biodegradable materials should be incentivized through regulatory mandates and market-driven policies.

Finally, healthcare organizations and pharmaceutical companies should prioritize sustainability in their corporate strategies, incorporating green objectives into their core business models. Public and private sector partnerships could play a pivotal role in establishing sustainability as a key driver of innovation and business growth within the pharmaceutical sector.

5.3 Future Research Directions and Technological Advancements

The future of greener pharmaceutical supply chains will depend heavily on technological advancements and continued research into sustainable practices. One key area for future research is the development of new green chemistry technologies that can be easily integrated into existing manufacturing processes. Research into alternative solvents, catalysts, and energy-efficient manufacturing methods will be crucial in reducing drug production's carbon footprint and environmental impact. Furthermore, studies on the scalability and cost-effectiveness of these new technologies will help pharmaceutical companies make more informed decisions when transitioning to sustainable practices.

Another promising direction for future research is the integration of digital technologies, such as artificial intelligence (AI) and machine learning (ML), into pharmaceutical manufacturing and distribution. These technologies have the potential to optimize supply chain logistics, reduce waste, and improve energy efficiency by analyzing vast amounts of data to identify inefficiencies and automate decision-making processes. AI-driven predictive models could also help in reducing unnecessary production, thereby minimizing waste.

Moreover, there is significant potential for innovation in sustainable packaging solutions. Research into biodegradable, compostable, or reusable packaging materials that maintain the necessary pharmaceutical safety and efficacy standards will be critical in reducing the industry's reliance on conventional plastic. Additionally, advancements in smart packaging, which can monitor environmental conditions and product integrity, could further improve the sustainability of drug distribution.

REFERENCES

[1] Abaku, E. A., & Odimarha, A. C. (2024). Sustainable supply chain management in the medical industry: a theoretical and practical examination. *International Medical Science Research Journal, 4*(3), 319-340.

[2] Abbey, A. B. N., Olaleye, I. A., Mokogwu, C., Olufemi-Phillips, A. Q., & Adewale, T. T. (2024). Developing inventory optimization frameworks to minimize economic loss in supply chain management.

[3] Adelodun, M. O., & Anyanwu, E. C. (2024a). A critical review of public health policies for radiation protection and safety.

[4] Adelodun, M. O., & Anyanwu, E. C. (2024b). Environmental and patient safety: Advances in radiological techniques to reduce radiation exposure.

[5] Adelodun, M. O., & Anyanwu, E. C. (2024c). Health Effects of Radiation: An Epidemiological Study on Populations near Nuclear Medicine Facilities. *Health*, *13*(9), 228-239.

[6] Alemede, V., Nwankwo, E. I., Igwama, G. T., Olaboye, J. A., & Anyanwu, E. C. (2024a). Designing state-level policies to support independent pharmacies in providing specialty care services in rural regions. *Magna Scientia Advanced Biology and Pharmacy*, *13*(1), 19-29.

[7] Alemede, V., Nwankwo, E. I., Igwama, G. T., Olaboye, J. A., & Anyanwu, E. C. (2024b). Pharmacists as educators: Enhancing patient understanding and access to specialty medications through community workshops. *Magna Scientia Advanced Biology and Pharmacy*, *13*(1), 1-9.

[8] Alkhouri, M. (2024). Pharmaceutical supply chain–new obstacles and challenges.

[9] Andraos, J., & Matlack, A. S. (2022). *Introduction to green chemistry*: CRC press.

[10] Arden, N. S., Fisher, A. C., Tyner, K., Lawrence, X. Y., Lee, S. L., & Kopcha, M. (2021). Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. *International Journal of Pharmaceutics*, *602*, 120554.

[11] Arowoogun, J. O., Ogugua, J. O., Odilibe, I. P., Onwumere, C., Anyanwu, E. C., & Akomolafe, O. (2024). COVID-19 vaccine distribution: A review of strategies in Africa and the USA. *World Journal of Advanced Research and Reviews*, *21*(1), 2729-2739.

[12] Ayo-Farai, O., Ogundairo, O., Maduka, C. P., Okongwu, C. C., Babarinde, A. O., & Sodamade, O. T. (2024). Digital health technologies in chronic disease management: a global perspective. *International Journal of Research and Scientific Innovation*, *10*(12), 533-551.

[13] Banji, A. F., Adekola, A. D., & Dada, S. A. (2024). Telepharmacy models improving chronic disease management in underserved, remote communities. *Int Med Sci Res J*, *4*(11).

[14] Baranes, A. I. (2016). *An original institutionalist approach to the structure, conduct, and performance of the pharmaceutical industry: the importance of intangible assets*: University of Missouri-Kansas City.

[15] Chaachouay, N., & Zidane, L. (2024). Plant-derived natural products: a source for drug discovery and development. *Drugs and Drug Candidates*, *3*(1), 184-207.

[16] David, B., Wolfender, J.-L., & Dias, D. A. (2015). The pharmaceutical industry and natural products: historical status and new trends. *Phytochemistry Reviews*, *14*, 299-315.

[17] Ding, B. (2018). Pharma Industry 4.0: Literature review and research opportunities in sustainable pharmaceutical supply chains. *Process Safety and Environmental Protection*, *119*, 115-130.

[18] Drakeford, O. M., & Majebi, N. L. (2024a). Advancing Personalized Autism Interventions in the U.S. A Data Analytics-Driven Conceptual Framework for Social Work. *International Journal of Engineering Research and Development*, *22*(12), 385-391

[19] Drakeford, O. M., & Majebi, N. L. (2024b). Reimagining autism research in the U.S.: A synergistic approach between social work, public health, and data analytic. *International Journal of Applied Research in Social Sciences*, *6*(12), 2916-2928.

[20] Drakeford, O. M., & Majebi, N. L. (2024c). Social work, analytics, and public health in autism: A conceptual approach to enhancing community health outcomes in U.S. underserved areas. *International Journal of Frontiers in Science and Technology Research,*, *7*(2), 100–108.

[21] Drakeford, O. M., & Majebi, N. L. (2024d). Transforming autism care in the U.S.: Conceptualizing a data-driven, social workbased framework for early diagnosis and intervention. *International Journal Of Frontiers in Medicine and Surgery Research*, *6*(2), 117–125 doi:DOI: https://doi.org/10.53294/ijfmsr.2024.6.2.0051

[22] Edoh, N. L., Chigboh, V. M., Zouo, S. J. C., & Olamijuwon, J. (2024). Improving healthcare decision-making with predictive analytics: A conceptual approach to patient risk assessment and care optimization.

[23] Eyo-Udo, N. L., Abbey, A. B. N., & Olaleye, I. A. (2024). Implementing Advanced Analytics for Optimizing Food Supply Chain Logistics and Efficiency. *International Journal of Research and Scientific Innovation*, *11*(12), 861-889.

[24] Fuller, R., Landrigan, P. J., Balakrishnan, K., Bathan, G., Bose-O'Reilly, S., Brauer, M., . . . Corra, L. (2022). Pollution and health: a progress update. *The Lancet Planetary Health*, *6*(6), e535-e547.

[25] G Ferreira, P., D Nicoletti, C., de C da Silva, F., & F Ferreira, V. (2016). Green Synthetic Routes to Pharmaceutical Drugs. *Current Green Chemistry*, *3*(3), 259-276.

[26] Kar, S., Sanderson, H., Roy, K., Benfenati, E., & Leszczynski, J. (2021). Green chemistry in the synthesis of pharmaceuticals. *Chemical Reviews*, *122*(3), 3637-3710.

[27] Kelvin-Agwu, M., Adelodun, M. O., Igwama, G. T., & Anyanwu, E. C. (2024). The role of biomedical engineers in enhancing patient care through efficient equipment management. *International Journal Of Frontiers in Medicine and Surgery Research*, *6*(1), 11-18.

[28] Kelvin-Agwu, M. C., Adelodun, M. O., Igwama, G. T., & Anyanwu, E. C. (2024a). Advancements in biomedical device implants: A comprehensive review of current technologies. *Int. J. Front. Med. Surg. Res*, *6*, 19-28.

[29] Kelvin-Agwu, M. C., Adelodun, M. O., Igwama, G. T., & Anyanwu, E. C. (2024b). Innovative approaches to the maintenance and repair of biomedical devices in resource-limited settings.

[30] Kelvin-Agwu, M. C., Adelodun, M. O., Igwama, G. T., & Anyanwu, E. C. (2024c). Integrating biomedical engineering with open-source telehealth platforms: enhancing remote patient monitoring in global healthcare systems. *International Medical Science Research Journal*, *4*(9).

[31] Krasnodębski, M. (2022). Lost green chemistries: history of forgotten environmental trajectories. *Centaurus*, *64*(2), 509-536.

[32] Kumar, S. A., Ananda Kumar, T. D., Beeraka, N. M., Pujar, G. V., Singh, M., Narayana Akshatha, H. S., & Bhagyalalitha, M. (2022). Machine learning and deep learning in data-driven decision making of drug discovery and challenges in high-quality data acquisition in the pharmaceutical industry. *Future Medicinal Chemistry*, *14*(4), 245-270.

[33] Llevot, A., & Meier, M. A. (2016). Renewability–a principle of utmost importance! *Green Chemistry*, *18*(18), 4800-4803.

[34] Low, Y. S., Halim, I., Adhitya, A., Chew, W., & Sharratt, P. (2016). Systematic framework for design of environmentally sustainable pharmaceutical supply chain network. *Journal of Pharmaceutical Innovation*, *11*, 250-263.

[35] Majebi, N. L., Adelodun, M. O., & Anyanwu, E. C. (2024). Integrating trauma-informed practices in US educational systems: Addressing behavioral challenges in underserved communities.

[36] Najmi, A., Javed, S. A., Al Bratty, M., & Alhazmi, H. A. (2022). Modern approaches in the discovery and development of plant-based natural products and their analogues as potential therapeutic agents. *Molecules*, *27*(2), 349.

[37] Nižetić, S., Djilali, N., Papadopoulos, A., & Rodrigues, J. J. (2019). Smart technologies for promotion of energy efficiency, utilization of sustainable resources and waste management. *Journal of Cleaner Production*, *231*, 565-591.

[38] Ogbeta, C. P., Mbata, A. O., & Katas, K. U. (2024). Developing Drug Formularies and Advocating for Biotechnology Growth: Pioneering Healthcare Innovation in Emerging Economies. *Quality assurance*, 30.

[39] Ogbonna, P. C., Oparaocha, E. T., Anyanwu, E. C., & Innocent, D. C. (2024). Physico-chemical analysis of hospital water in selected secondary health facilities in Bayelsa state, Nigeria.

[40] Olaleye, I. A., Mokogwu, C., Olufemi-Phillips, A. Q., & Adewale, T. T. (2024). Real-time inventory optimization in dynamic supply chains using advanced artificial intelligence. *Journal name if available*.

[41] Peake, B. M., Braund, R., Tong, A., & Tremblay, L. A. (2015). *The Life-cycle of Pharmaceuticals in the Environment*: Elsevier.

[42] Quiñones, O. G., & Pierre, M. B. (2019). Cutaneous application of celecoxib for inflammatory and cancer diseases. *Current Cancer Drug Targets*, *19*(1), 5-16.

[43] Rame, R., Purwanto, P., & Sudarno, S. (2024). Industry 5.0 and sustainability: An overview of emerging trends and challenges for a green

future. *Innovation and Green Development*, *3*(4), 100173.

[44] Sheldon, R. A. (2018). Metrics of green chemistry and sustainability: past, present, and future. *ACS Sustainable Chemistry & Engineering*, *6*(1), 32-48.

[45] Sherman, J. D., Thiel, C., MacNeill, A., Eckelman, M. J., Dubrow, R., Hopf, H., . . . Forbes, M. (2020). The green print: advancement of environmental sustainability in healthcare. *Resources, Conservation and Recycling*, *161*, 104882.

[46] Singh, R. K., Kumar, R., & Kumar, P. (2016). Strategic issues in pharmaceutical supply chains: a review. *International Journal of Pharmaceutical and Healthcare Marketing*, *10*(3), 234-257.

[47] Tien, N. H., Anh, D. B. H., & Thuc, T. D. (2019). Global supply chain and logistics management. In: Academic Publications, Dehli.

[48] Veleva, V. R., Cue Jr, B. W., & Todorova, S. (2018). Benchmarking green chemistry adoption by the global pharmaceutical supply chain. *ACS Sustainable Chemistry & Engineering*, *6*(1), 2-14.

[49] Venkatesh, V., Kang, K., Wang, B., Zhong, R. Y., & Zhang, A. (2020). System architecture for blockchain based transparency of supply chain social sustainability. *Robotics and Computer-Integrated Manufacturing*, *63*, 101896.

[50] Wingate, G. (2016). Pharmaceutical computer systems validation: quality assurance, risk management and regulatory compliance.